EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia

Tzu-Ting Chen, Ching-Chan Lin, Wen-Jyi Lo, Ching-Yun Hsieh, Ming-Yu Lein, Che-Hung Lin, Chen-Yuan Lin, Li-Yuan Bai, Chang-Fang Chiu, Su-Peng Yeh

Cancers · 07.03.2024 · 16 (6) · 1082

DOI: 10.3390/cancers16061082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.03.2024. Verfasst von Tzu-Ting Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University Hospital, An Nan Hospital, China Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is rarely recommended for unfit patients with newly diagnosed acute myeloid leukemia (AML). Patient survival can improve with venetoclax plus azacitidine (VEN plus AZA). However, the long-term outcome of this treatment strategy is still unsatisfactory. The high response and low treatment toxicity rates of patients receiving VEN plus AZA can provide an opportunity for HSCT among unfit patients. Nevertheless, the outcomes and complications of VEN plus AZA, followed by HSCT, remain unclear.

Methods

This single-center retrospective study aimed to compare patients with newly diagnosed AML receiving VEN plus AZA as induction therapy (n = 27) to those receiving the conventional I3A7 regimen as induction therapy (n = 34).

Result

The 1-year overall survival, relapse, and non-relapse mortality rates in the two groups were similar. The cytogenetic risks and the hematopoietic cell transplantation-specific comorbidity index are the most significant predictive factors of overall survival.

Conclusion

In older patients unfit for intensive chemotherapy, a low-intensity regimen with VEN plus AZA is a suitable bridge therapy. Furthermore, allo-HSCT is feasible and can be a curative option.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic stem cell transplantationazacytidinevenetoclax

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, An Nan Hospital, Tainan 700, Taiwan.
  • College of Medicine, China Medical University, Taichung 404, Taiwan.
  • Stem Cell Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan.

Förderung

  • China Medical University Hospital
  • An Nan Hospital, China Medical University

Zitieren

APA

Chen, T. T., Lin, C. C., Lo, W. J., Hsieh, C. Y., Lein, M. Y., Lin, C. H., Lin, C. Y., Bai, L. Y., Chiu, C. F., & Yeh, S. P. (2024). Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Cancers, 16(6), 1082. https://doi.org/10.3390/cancers16061082

Vancouver

Chen TT, Lin CC, Lo WJ, Hsieh CY, Lein MY, Lin CH, et al. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Cancers. 2024;16(6):1082. doi:10.3390/cancers16061082

BibTeX
@article{Chen2024,
  author = {Chen, Tzu-Ting and Lin, Ching-Chan and Lo, Wen-Jyi and Hsieh, Ching-Yun and Lein, Ming-Yu and Lin, Che-Hung and Lin, Chen-Yuan and Bai, Li-Yuan and Chiu, Chang-Fang and Yeh, Su-Peng},
  title = {Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {1082},
  doi = {10.3390/cancers16061082}
}
Kostenlos starten →